Bristol/Teva “Authorized” Generic Agreement Approved By FTC

A settlement allowing Teva to launch generic carboplatin in June is not anti-competitive, the Federal Trade Commission says. The agreement encourages price competition and gives Teva an incentive to launch under an ANDA as soon as possible, FTC says.